Literature DB >> 2106351

Retroviral-mediated transfer and amplification of a functional human factor VIII gene.

D I Israel1, R J Kaufman.   

Abstract

Hemophilia A results from a deficiency in factor VII (FVIII), a cofactor in the intrinsic pathway of blood coagulation. As an approach toward genetic therapy of this disease, we constructed a retroviral vector encoding human FVIII and a selectable and amplifiable genetic marker, human adenosine deaminase (Ada). A retrovirus packaging line was transfected with this vector and stable transformants were selected for Ada expression. Isolated transformants produced both FVIII activity in the conditioned medium and retrovirus capable of transferring the Ada selectable marker and FVIII expression to the mouse 3T3 fibroblasts. Selection of virus-producer cell lines for increasing levels of Ada expression yielded a 20-fold increase in both FVIII expression and viral titer. Similarly, selection of infected 3T3 fibroblasts for Ada gene amplification yielded a 20-fold increase in FVIII expression. The results demonstrate the feasibility of retrovirus-mediated transfer of human FVIII, and also the utility of selection for gene amplification to increase retrovirus titers in producer cell lines as well as expression levels in infected cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2106351

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

2.  Advancements in gene transfer-based therapy for hemophilia A.

Authors:  Christopher B Doering; H Trent Spencer
Journal:  Expert Rev Hematol       Date:  2009-12       Impact factor: 2.929

3.  The human clotting factor VIII cDNA contains an autonomously replicating sequence consensus- and matrix attachment region-like sequence that binds a nuclear factor, represses heterologous gene expression, and mediates the transcriptional effects of sodium butyrate.

Authors:  F J Fallaux; R C Hoeben; S J Cramer; D J van den Wollenberg; E Briët; H van Ormondt; A J van Der Eb
Journal:  Mol Cell Biol       Date:  1996-08       Impact factor: 4.272

4.  Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.

Authors:  T VandenDriessche; V Vanslembrouck; I Goovaerts; H Zwinnen; M L Vanderhaeghen; D Collen; M K Chuah
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

5.  In vivo production of human factor VII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery.

Authors:  K Zatloukal; M Cotten; M Berger; W Schmidt; E Wagner; M L Birnstiel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

6.  Prospects for the use of artificial chromosomes and minichromosome-like episomes in gene therapy.

Authors:  Sara Pérez-Luz; Javier Díaz-Nido
Journal:  J Biomed Biotechnol       Date:  2010-08-24

7.  Engineering Factor Viii for Hemophilia Gene Therapy.

Authors:  Sean A Roberts; Biao Dong; Jenni A Firrman; Andrea R Moore; Nianli Sang; Weidong Xiao
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-21

8.  Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice.

Authors:  V J Dwarki; P Belloni; T Nijjar; J Smith; L Couto; M Rabier; S Clift; A Berns; L K Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

Review 9.  The Immune Response to the fVIII Gene Therapy in Preclinical Models.

Authors:  Seema R Patel; Taran S Lundgren; H Trent Spencer; Christopher B Doering
Journal:  Front Immunol       Date:  2020-04-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.